GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Cash Flow from Financing

Prostatype Genomics AB (OSTO:PROGEN) Cash Flow from Financing : kr59.75 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Prostatype Genomics AB received kr36.77 Mil more from issuing new shares than it paid to buy back shares. It spent kr5.83 Mil paying down its debt. It paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received kr0.00 Mil from paying cash dividends to shareholders. It received kr0.00 Mil on other financial activities. In all, Prostatype Genomics AB earned kr30.94 Mil on financial activities for the six months ended in Dec. 2024.


Prostatype Genomics AB Cash Flow from Financing Historical Data

The historical data trend for Prostatype Genomics AB's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Cash Flow from Financing Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial 7.38 23.05 18.85 28.91 59.75

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 19.05 20.48 8.43 28.81 30.94

Prostatype Genomics AB Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Prostatype Genomics AB's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Prostatype Genomics AB's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr59.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Prostatype Genomics AB's issuance of stock for the six months ended in Dec. 2024 was kr36.77 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Prostatype Genomics AB's repurchase of stock for the six months ended in Dec. 2024 was kr0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Prostatype Genomics AB's net issuance of debt for the six months ended in Dec. 2024 was kr-5.83 Mil. Prostatype Genomics AB spent kr5.83 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Prostatype Genomics AB's net issuance of preferred for the six months ended in Dec. 2024 was kr0.00 Mil. Prostatype Genomics AB paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Prostatype Genomics AB's cash flow for dividends for the six months ended in Dec. 2024 was kr0.00 Mil. Prostatype Genomics AB received kr0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Prostatype Genomics AB's other financing for the six months ended in Dec. 2024 was kr0.00 Mil. Prostatype Genomics AB received kr0.00 Mil on other financial activities.


Prostatype Genomics AB Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB Business Description

Traded in Other Exchanges
N/A
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB Headlines

No Headlines